Targeting BRCA2 deficiency with GSK3 inhibitors

Targeting BRCA2 deficiency with GSK3 inhibitors

<p>BRCA1 and BRCA2 tumour suppressors are essential for homologous recombination-mediated double-strand break repair and replication fork protection. Therefore, BRCA1 and BRCA2 are essential for cell viability. Deactivating mutations in one of these genes lead to genome instability and are ass...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awdur:	Zonderland, G
Awduron Eraill:	Tarsounas, M
Fformat:	Traethawd Ymchwil
Cyhoeddwyd:	2017

Eitemau Tebyg

Chlorambucil targets BRCA1/2‐deficient tumours and counteracts PARP inhibitor resistance
gan: Tacconi, E, et al.
Cyhoeddwyd: (2019)

Chlorambucil targets BRCA1/2‐deficient tumours and counteracts PARP inhibitor resistance
gan: Eliana MC Tacconi, et al.
Cyhoeddwyd: (2019-05-01)

Targeting BRCA1 and BRCA2 deficiencies with G-quadruplex-interacting compounds
gan: Zimmer, J, et al.
Cyhoeddwyd: (2016)

Targeting the BRCA1/2 deficient cancer with PARP inhibitors: Clinical outcomes and mechanistic insights
gan: Ashwin Ragupathi, et al.
Cyhoeddwyd: (2023-03-01)

Novel approaches for targeting BRCA2-deficient tumour cells
gan: Tacconi, E
Cyhoeddwyd: (2015)

Sirtuin inhibition is synthetic lethal with BRCA1 or BRCA2 deficiency
gan: Ilirjana Bajrami, et al.
Cyhoeddwyd: (2021-11-01)

GSK-3 inhibitors induce chromosome instability
gan: Staples Oliver D, et al.
Cyhoeddwyd: (2007-08-01)

A transcription-based mechanism for oncogenic β-catenin-induced lethality in BRCA1/2-deficient cells
gan: Rebecca A. Dagg, et al.
Cyhoeddwyd: (2021-08-01)

Lithium and Therapeutic Targeting of GSK-3
gan: Melinda E. Snitow, et al.
Cyhoeddwyd: (2021-01-01)

The Role of GSK-3 in Cancer Immunotherapy: GSK-3 Inhibitors as a New Frontier in Cancer Treatment
gan: Giuseppa Augello, et al.
Cyhoeddwyd: (2020-06-01)

Targeting GPX4-mediated ferroptosis protection sensitizes BRCA1-deficient cancer cells to PARP inhibitors
gan: Xuexia Xie, et al.
Cyhoeddwyd: (2024-10-01)

Machine Learning for Discovery of GSK3β Inhibitors
gan: Patricia A. Vignaux, et al.
Cyhoeddwyd: (2020-10-01)

GSK-3 inhibitors: preclinical and clinical focus on CNS
gan: Hagit eEldar-Finkelman, et al.
Cyhoeddwyd: (2011-10-01)

GSK-3 Inhibitors and Tooth Repair: An Ethical Analysis
gan: Sorin Hostiuc, et al.
Cyhoeddwyd: (2019-01-01)

Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer
gan: Shicheng Yang, et al.
Cyhoeddwyd: (2023-05-01)

A Novel PARP Inhibitor YHP-836 For the Treatment of BRCA-Deficiency Cancers
gan: Tingting Du, et al.
Cyhoeddwyd: (2022-07-01)

PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting
gan: Karolina N. Dziadkowiec, et al.
Cyhoeddwyd: (2017-02-01)

BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity.
gan: Tacconi, E, et al.
Cyhoeddwyd: (2017)

Identification of a RAD52 Inhibitor Inducing Synthetic Lethality in BRCA2-Deficient Cancer Cells
gan: Qianye Yang, et al.
Cyhoeddwyd: (2021-04-01)

Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance
gan: Zatreanu, D, et al.
Cyhoeddwyd: (2021)

Targeting of CRMP-2 to the primary cilium is modulated by GSK-3β.
gan: Young Ou, et al.
Cyhoeddwyd: (2012-01-01)

BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity
gan: Eliana MC Tacconi, et al.
Cyhoeddwyd: (2017-07-01)

Inhibitors of Rho kinases (ROCK) induce multiple mitotic defects and synthetic lethality in BRCA2-deficient cells
gan: Julieta Martino, et al.
Cyhoeddwyd: (2023-04-01)

The GSK3 kinase inhibitor lithium produces unexpected hyperphosphorylation of β-catenin, a GSK3 substrate, in human glioblastoma cells
gan: Ata ur Rahman Mohammed Abdul, et al.
Cyhoeddwyd: (2018-01-01)

Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance
gan: Diana Zatreanu, et al.
Cyhoeddwyd: (2021-06-01)

The inhibitors of cyclin-dependent kinases and GSK-3β enhance osteoclastogenesis
gan: Yosuke Akiba, et al.
Cyhoeddwyd: (2016-03-01)

Novel reporter alleles of GSK-3α and GSK-3β.
gan: William B Barrell, et al.
Cyhoeddwyd: (2012-01-01)

Correction: Inhibitors of Rho kinases (ROCK) induce multiple mitotic defects and synthetic lethality in BRCA2-deficient cells
gan: Julieta Martino, et al.
Cyhoeddwyd: (2023-11-01)

Targeting GSK3 and Associated Signaling Pathways Involved in Cancer
gan: Przemysław Duda, et al.
Cyhoeddwyd: (2020-04-01)

BRCA1 and BRCA2 deficient tumour models generate distinct ovarian tumour microenvironments and differential responses to therapy
gan: Salar Farokhi Boroujeni, et al.
Cyhoeddwyd: (2023-11-01)

GSK-3α Is a Novel Target of CREB and CREB-GSK-3α Signaling Participates in Cell Viability in Lung Cancer.
gan: Sin-Aye Park, et al.
Cyhoeddwyd: (2016-01-01)

Intrinsic resistance of HIV-2 and SIV to the maturation inhibitor GSK2838232
gan: Robert A. Smith, et al.
Cyhoeddwyd: (2023-01-01)

Intrinsic resistance of HIV-2 and SIV to the maturation inhibitor GSK2838232.
gan: Robert A Smith, et al.
Cyhoeddwyd: (2023-01-01)

Glycogen synthase kinase 3 (GSK-3) and its inhibitors : drug discovery and development /
gan: Martinez, Ana, 1961-, et al.
Cyhoeddwyd: (2006)

Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies
gan: Xia Ding, et al.
Cyhoeddwyd: (2016-08-01)

1111 Targeting lipid metabolism to improve PARP inhibitor response in BRCA-associated TNBC
gan: Geoffrey I Shapiro, et al.
Cyhoeddwyd: (2023-11-01)

BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2.
gan: Melissa S Cline, et al.
Cyhoeddwyd: (2018-12-01)

Role of GSK-3β Inhibitors: New Promises and Opportunities for Alzheimer’s Disease
gan: Suggala Ramya Shri, et al.
Cyhoeddwyd: (2023-11-01)

Discovery of Novel Imidazopyridine GSK-3β Inhibitors Supported by Computational Approaches
gan: Rosa Buonfiglio, et al.
Cyhoeddwyd: (2020-05-01)

Computational study of some cancer drugs as potent inhibitors of GSK3β
gan: David Ebuka Arthur, et al.
Cyhoeddwyd: (2020-11-01)